[1] 李迪,李艳.HCMV-DNA载量与婴儿巨细胞病毒性肝炎的关系.检验医学与临床,2017,14:2700-2701,2704.
[2] 沈丹,黄少军,汪晶晶.三种标本CMV-DNA含量检测在儿童巨细胞病毒性肝炎诊断和治疗监测中的应用.肝脏,2015,20:35-37.
[3] 封洁,庄丽丽,朱亮华,等.婴儿巨细胞病毒性肝炎36例临床分析.江苏医药,2015,41:1646-1648.
[4] 张雪玲,李建绪.茵栀黄联合更昔洛韦治疗早产儿巨细胞病毒性肝炎的疗效及对患儿IL-8、INF-γ、D-二聚体和vWF的影响.中国妇幼保健,2017,32:5338-5341.
[5] 廖凤明.更昔洛韦分次给药与一次给药治疗小儿巨细胞病毒性肝炎疗效比较.肝脏,2016,21:156-157.
[6] 邢芳华,王荣坤,邢舒旺,等.更昔洛韦联合大剂量丙种球蛋白治疗婴儿巨细胞病毒性肝炎的疗效观察.现代生物医学进展,2018,18:2763-2767.
[7] 张小灵.腺苷蛋氨酸与门冬氨酸钾镁对病毒性肝炎患者临床疗效的对比分析.抗感染药学,2015,12:295-297.
[8] 李志林,黄汉光,邓恩平.血浆D-二聚体水平与肝硬化患者病因、肝功能分级、并发症的关联分析.中国医学创新,2017,14:112-115.
[9] 刘岚,谭梅军,万盛华,等.巨细胞病毒性肝炎婴儿血清IFN-γ、IL-10、IL-17的表达及意义.江西医药,2016,51:974-976.
[10] Chen Y,Xu LP,Liu XY,et al. Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus. J Clin Virol,2016,75:10-15.
[11] Yagmur G,Ziyade N,Elgormus N,et al. Postmortem diagnosis of cytomegalovirus and accompanying other infection agents by real-time PCR in cases of sudden unexpected death in infancy (SUDI). J Forensic Leg Med,2016,38:18-23.
[12] 刘振国,李继兴,王敏.更昔洛韦与还原型谷胱甘肽联合治疗巨细胞病毒肝炎患儿的疗效及其对外周血T淋巴细胞水平的影响.实用肝脏病杂志,2018,21:283-284.
[13] 王玉梅.丁二磺酸腺苷蛋氨酸与更昔洛韦联合治疗婴儿巨细胞病毒性肝炎疗效观察.中国医学创新,2015,12:1-3. |
